Charles A. Rowland Jr - Jun 2, 2021 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role: Director
Signature: /s/ Ariel Hurley, Attorney-in-Fact
Stock symbol: BPMC
Transactions as of: Jun 2, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/4/2021, 04:16 PM
Previous filing: Aug 3, 2022
Next filing: Jun 11, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BPMC	Common Stock	Award	$0	+2.25K	+63.17%	$0.00	5.81K	Jun 2, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BPMC	Stock Option (Right to Buy)	Award	$0	+4.5K		$0.00	4.5K	Jun 2, 2021	Common Stock	4.5K	$87.13	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022.

Content

The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022.